Kexing Biopharm's clinical trial application accepted for Human Interferon α2b Effervescent Capsule

Release date:2022 - 06 - 27

On the evening of June 20, 2022, Kexing Biopharm Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that it had received the Notice of Acceptance, an administrative license document issued by the National Medical Products Administration, indicating that its clinical trial application for "Human Interferon α2b Vaginal Effervescent Capsule" was accepted.

Basic Information of Drug for Registration

1. Product Name: Human Interferon α2b Vaginal Effervescent Capsule
2. Application Item: clinical trial for registration of drugs produced in China
3. Indication: It is proposed for the treatment of cervicitis caused by virus, with or without vaginitis.
4. Dosage Form: Capsule

The promotion of the R&D of Human Interferon α2b Vaginal Effervescent Capsules will help the Company enrich the dosage forms of interferon products, strengthen its competitiveness in the antiviral field, improve the overall R&D capacity, and enhance the long-term profitability.

About Human Interferon α2b Vaginal Effervescent Capsule

Interferon has a good therapeutic effect on chronic cervicitis. The common dosage forms thereof are effervescent capsule and effervescent tablet. Effervescent capsule achieves better compliance than effervescent tablet. The Human Interferon α2b Vaginal Effervescent Capsule developed by Kexing Biopharm is proposed to treat cervicitis caused by virus, with or without vaginitis, and its registration classification is Class 2.2 therapeutic biological products (defined as those adding new indications that have not been approved in China and abroad or changing the target population).

Previous Back to List Next